Immunovia launches rights issue to raise up to SEK 63M

Swedish diagnostics firm Immunovia announced a rights issue targeting up to SEK 63 million before costs, a capital raise that signals ongoing cash burn and potential dilution for existing shareholders. The move follows the company's strategic pivot toward its IMMray PanCan-d test, but financial sustainability remains uncertain. This is a routine equity financing event for a small-cap biotech, with limited macro or sector-wide implications.